7,500 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by APEIRON CAPITAL Ltd

APEIRON CAPITAL Ltd acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,500 shares of the company’s stock, valued at approximately $468,000. TransMedics Group makes up about 0.2% of APEIRON CAPITAL Ltd’s investment portfolio, making the stock its 13th biggest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Amalgamated Bank raised its stake in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC lifted its holdings in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares during the last quarter. Arizona State Retirement System grew its position in shares of TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after acquiring an additional 186 shares in the last quarter. Venturi Wealth Management LLC grew its position in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after acquiring an additional 219 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,459 shares of company stock valued at $1,802,244 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. TD Cowen decreased their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Oppenheimer restated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Up 9.5 %

Shares of TransMedics Group stock opened at $75.63 on Tuesday. TransMedics Group, Inc. has a 1-year low of $58.27 and a 1-year high of $177.37. The company has a market capitalization of $2.54 billion, a P/E ratio of 80.46 and a beta of 2.12. The business’s fifty day moving average price is $75.83 and its two-hundred day moving average price is $123.23. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.12) EPS. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.